All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Jounce Therapeutics Inc. has quit enrolling Emerge, an open-label phase II study of its inducible T-cell co-stimulator agonist, vopratelimab, the company’s most advanced candidate.